99780-88-8

Basic information

• Product Name: 2H-Pyrazino[2,1-a]isoquinoline,1,3,4,6,7,11b-hexahydro-,(R)-(9CI)
• Synonyms: 2H-Pyrazino[2,1-a]isoquinoline,1,3,4,6,7,11b-hexahydro-,(R)-(9CI)
• CAS NO: 99780-88-8
• Molecular Formula: C12H16N2
• Molecular Weight: 0
• Product Categories: PIPERIDINE
• Mol File: 99780-88-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2H-Pyrazino[2,1-a]isoquinoline,1,3,4,6,7,11b-hexahydro-,(R)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyrazino[2,1-a]isoquinoline,1,3,4,6,7,11b-hexahydro-,(R)-(9CI)(99780-88-8)
• EPA Substance Registry System: 2H-Pyrazino[2,1-a]isoquinoline,1,3,4,6,7,11b-hexahydro-,(R)-(9CI)(99780-88-8)

Safety Data

• Hazardous Substances Data: 99780-88-8(Hazardous Substances Data)

Upstream product

• 55375-92-3 (R)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 99746-73-3 (S)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 58971-11-2 2-(3-bromophenyl)ethanamine 

Relevant articles and documents

SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to a compound of formula (I) wherein R1/R2 are independently from each other hydrogen or halogen; L is a bond, -NH-, -C(O)NH-, -NHC(O)- or NHC(O)NH-; R is hydrogen, lower alkyl, cycloalkyl, benzyl, phenyl or a five or six membered heteroaryl group, wherein phenyl and the heteroaryl groups are optionally substituted by one or two substituents, selected from halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl or di-lower alkyl amino or R is halogen if L is a bond. or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers. The compounds of formulas (I) have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1 and may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.